IRAK4/TrkA - Evommune/ Dermira
Alternative Names: Interleukin-1 receptor-associated kinase 4/Tropomyosin receptor kinase A inhibitor - Evommune/ DermiraLatest Information Update: 12 Apr 2022
At a glance
- Originator Dermira
- Developer Evommune
- Class Anti-inflammatories; Skin disorder therapies; Small molecules
- Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors; TrkA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis; Rosacea
Most Recent Events
- 12 Apr 2022 Discontinued - Preclinical for Atopic dermatitis in USA (unspecified route) (Evommune pipeline, April 2022)
- 12 Apr 2022 Discontinued - Preclinical for Rosacea in USA (unspecified route) (Evommune pipeline, April 2022)
- 15 Sep 2021 Preclinical trials in Atopic dermatitis in USA (unspecified route) before September 2021 (Evommune website, September 2021)